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InTROduCTIOn
Infliximab, a chimeric IgG1 monoclonal antibody that inhibits tumour necrosis factor alpha (TNFα), is a medicine for the treatment of several immune-mediated inflammatory
Key messages
What is already known about this subject?
► treatment period 1 of the reFlectiOnS B537-02 study confirmed that PF-06438179/gP1111 (PF-SZ-iFX) has similar efficacy, safety and immunogenicity compared with european reference infliximab (ref-iFX) in patients with moderate-to-severe, active rheumatoid arthritis.
What does this study add?
► these results from treatment period 2 of the same study continue to demonstrate similar efficacy, safety and immunogenicity of PF-SZ-iFX compared with ref-iFX after long-term follow-up and treatment switch from ref-iFX.
How might this impact on clinical practice?
► these results add to the totality of evidence for PF-SZ-iFX and continue to support the use of PF-SZ-iFX as an infliximab biosimilar.
RMD Open RMD Open RMD Open diseases, including rheumatoid arthritis (RA), Crohn's disease and ulcerative colitis. 1 2 PF-06438179/GP1111 (PF-SZ-IFX) is a biosimilar of infliximab that is approved in the European Union, 3 
Japan
4 and the USA. 5 PF-SZ-IFX was developed by Pfizer. In February 2016, Sandoz acquired the biosimilar development, commercialisation and manufacturing rights from Pfizer for the 28 countries in the European Union plus Norway, Iceland and Liechtenstein. Pfizer retains commercialisation and manufacturing rights for the remaining countries of the world.
Biosimilars are cost-effective versions of their reference medicine that have undergone regulatory review and received regulatory approval based on a totality of evidence showing no meaningful difference compared with the reference medicine; thus, biosimilars are normally able to be approved for use in the same indications. [6] [7] [8] Switching patients from reference medicines to biosimilars can provide cost savings 9 10 and similar efficacy [11] [12] [13] ; consequently, biosimilars offer the potential to expand patient access to important, but expensive, biologic medicines.
14 Despite the potential benefits, there are still challenges and barriers to the uptake of biosimilars, including a desire for more information about biosimilars (eg, long-term efficacy and safety data) and concerns about the potential for increased immunogenicity after switching from a reference medicine to a biosimilar, or with multiple switching. [14] [15] [16] To date, the totality of evidence demonstrates that PF-SZ-IFX has an identical amino acid sequence and similar biological activity to reference infliximab (Remicade; ref-IFX) as demonstrated in preclinical studies 17 ; a similar pharmacokinetic profile in healthy volunteers to ref-IFX; and comparable immunogenicity with ref-IFX. 18 The REFLECTIONS B537-02 study was a confirmatory phase III, double-blind, randomised, active-controlled trial. 19 In treatment period 1 (TP1; weeks 0-30) similar efficacy, safety and immunogenicity of PF-SZ-IFX were shown compared with ref-IFX sourced in the European Union in patients with moderate-to-severe, active RA and inadequate response to methotrexate. 19 Here, we report long-term data (up to 54 weeks) on the efficacy, safety and immunogenicity of PF-SZ-IFX compared with ref-IFX, including data for patients after a single switch from ref-IFX to PF-SZ-IFX after 30 weeks, from TP2 (weeks 30-54) of the REFLECTIONS B537-02 study.
MeTHOds study conduct
An independent data monitoring committee was responsible for monitoring safety and study conduct. All patients provided written informed consent before entering the study. Since all three treatment periods were part of the same study, no additional informed consent was required prior to rerandomisation in TP2. study design and treatment REFLECTIONS B537-02 was a multinational, randomised, double-blind, parallel-group, 78-week study comparing the efficacy, safety and immunogenicity of PF-SZ-IFX with ref-IFX (online supplementary figure S1 ). 19 The REFLECTIONS B537-02 study was split into three distinct treatment periods; TP2 (weeks 30-54) is the focus of this manuscript. As described previously, during TP1 (weeks 0-30), patients were randomised Subject unique identifiers assigned at the screening visit were associated with patients' randomisation and rerandomisation schedules and treatment assignments, and were retained throughout the study.
Patients continued to receive a stable dose of methotrexate (10-25 mg/week) and folic/folinic acid throughout the study. The investigators were asked to reconsider treatment in patients who did not show improvement, and continuation of treatment was at the discretion of the treating physician. TP3 was an openlabel extension that assessed the longer term efficacy and safety of PF-SZ-IFX from weeks 54 to 78.
Patients
Briefly, the key inclusion criteria were male and female patients aged ≥18 years with moderate-to-severe, active RA (≥6 tender and ≥6 swollen joints, high-sensitivity C reactive protein level ≥10 mg/L, and on a stable dose of methotrexate [10-25 mg/week for ≥4 weeks]); a diagnosis of RA based on the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA for ≥4 months; and class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA. Patients were excluded if they had current or prior treatment with infliximab or lymphocyte-depleting therapies (eg, rituximab, alemtuzumab); however, they were allowed ≤2 doses of one non-depleting, non-infliximab biologic if discontinued ≥12 weeks or five half-lives (whichever was longer) prior to the first dose of study drug. Further details have been described previously. 19 endpoints The primary endpoint was the percentage of patients achieving ≥20% improvement in ACR response (ACR20) from study baseline (week 0), evaluated at week 14 during TP1, as previously reported. 19 Secondary efficacy endpoints included ≥20%/50%/70% improvement in ACR response (ACR20/50/70) from study baseline; change from study baseline in Disease Activity Score in 28 Joints Based on High-Sensitivity C Reactive Protein (DAS28-CRP); DAS28-CRP remission, Rheumatoid arthritis Rheumatoid arthritis Rheumatoid arthritis defined as a DAS28-CRP score <2.6; EULAR response; ACR/EULAR remission; change in tender and swollen joint counts from study baseline; high-sensitivity CRP and its change from study baseline; and Health Assessment Questionnaire-Disability Index (HAQ-DI) and its change from study baseline. During TP2, secondary endpoints were assessed at weeks 38, 46 and 54. Safety and tolerability were evaluated throughout the study based on the reporting of adverse events (AEs), treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESIs).
Immunogenicity was evaluated based on the number and percentage of patients in TP2 who had ≥1 postdose sample that tested positive for antidrug antibodies (ADAs); neutralising antibodies (NAb) were analysed in ADA-positive samples only. The methods used for evaluating immunogenicity are as previously described by Cohen et al. 19 
statistical analyses
The study was powered (≥85%) to demonstrate equivalence using a prespecified symmetric margin of ±13.5% with a two-sided 95% CI when assuming ACR20 response rates of 57.5% at week 14 (TP1) in both arms.
The secondary efficacy endpoints were summarised using descriptive statistics, based on the intent-to-treat population, defined as all patients who were randomised to study treatment in TP2.
Safety and immunogenicity endpoints were analysed descriptively for the safety population (all patients who received ≥1 dose of study drug in TP2).
No formal hypothesis testing was conducted for any secondary, safety or immunogenicity endpoints, or for any endpoints measured during TP2.
ResulTs

Patients and treatment
At study entry, 650 patients were randomised (PF-SZ-IFX, n=324; ref-IFX, n=326), as previously reported. 19 At week 30, 566 patients who completed TP1 entered TP2. Of these, 280 continued PF-SZ-IFX treatment, and 286 patients treated with ref-IFX in TP1 were rerandomised to continue ref-IFX (n=143) or to switch to PF-SZ-IFX (n=143). Overall, 506 patients (89.4%) completed TP2 with similar rates of completion across the three treatment groups.
No clinically meaningful differences in baseline demographics were observed between the three treatment groups in TP2, or between those who entered TP2 versus TP1 (data not shown). Disease characteristics at week 30, prior to the first infusion of study medication in TP2, were not notably different between the three treatment groups but did reflect improvements from baseline at week 0 of TP1 (table 1) . At week 30 and prior to the first infusion of study medication in TP2, the mean DAS28-CRP value was 3.8 in all groups, reflecting mean changes from study baseline (week 0) of -2. groups, respectively. Throughout TP2, the mean change in DAS28-CRP from baseline remained comparable between groups at all TP2 visits (figure 2). At week 54, the mean DAS28-CRP values were 3.4, 3.6 and 3. Overall, EULAR response rates, DAS28-CRP remission, mean tender/swollen joint counts and mean change in high-sensitivity CRP from baseline were comparable across the three treatment groups at weeks 30 and 54 (online supplementary table S1).
safety The median duration of treatment across all three treatment groups was 46.1 weeks between the first infusion of TP1 and the last infusion of TP2. No patient required a dose reduction in any group during TP2.
Treatment-emergent adverse events
Overall, the incidence of TEAEs and treatment discontinuations due to TEAEs during TP2 was low and comparable across the treatment groups ( The most frequently reported IRR TEAEs in TP2 were hypotension (1.1%, 0.7% and 0%), nausea (0.4%, 2.1% and 0%), pruritus (0.4%, 1.4% and 0%) and vomiting (0%, 1.4% and 0.7%). Across all treatment arms, very few serious (0.4%), grade 3 (0.7%) or grade 4 (0.2%) IRR TEAEs, and no grade 5 IRR TEAEs, were reported.
The most frequently reported infection-related TEAEs in TP2 were nasopharyngitis (3.2%, 3.5% and 1.4%), upper respiratory tract infection (2.1%, 1.4% and 2.1%), bronchitis (1.1%, 2.1% and 1.4%) and urinary tract infection (1.1%, 1.4% and 2.1%). Across all treatment arms, 1.1% reported serious infectious TEAEs and 1.4% of patients reported grade 3 or higher infectious TEAEs. The number of patients with ADAs and NAbs was comparable and generally stable over time between all three treatment groups (figure 3). A total of 288 patients (50.9%) in the TP2 population initially developed ADAs during TP1, and nearly all (n=270; 93.8%) continued to test positive for ADAs during TP2.
Aes leading to treatment discontinuation
Rheumatoid arthritis Rheumatoid arthritis Rheumatoid arthritis
As expected, ADA-positive patients had lower mean serum PF-SZ-IFX or ref-IFX trough concentrations than ADA-negative patients, but within each ADA subgroup the mean concentrations were generally comparable across the three treatment groups during TP2 (online supplementary table S2).
The majority of patients who developed ADAs had no hypersensitivity events and did not experience IRRs during TP2.
Of the 288 patients who were identified as ADA-positive in TP1, 32 experienced hypersensitivity TEAEs in TP2 (11 [7. These data provide additional reassurance to physicians who may want to see additional data compared with that required by regulatory agencies, and for those who have concerns about the potential for increased immunogenicity after switching from a reference medicine to a biosimilar. [14] [15] [16] The primary endpoint of the study, ACR20 response assessed during TP1 at week 14, was met by similar percentages of patients treated with PF-SZ-IFX (62.7%) and ref-IFX (64.1%) and maintained until the end of the treatment period at week 30. At week 30 and after rerandomisation into the TP2 treatment groups, the ACR20 response rate remained comparable among patients who entered TP2, and these treatment responses were maintained for the duration of TP2 in all three treatment groups. Regulatory authorities consider ACR20 to be a sensitive efficacy endpoint in RA, 20 and these findings therefore confirm continued comparable efficacy other treatment groups, but these differences were not considered to be of clinical relevance by the study investigators. Small differences between the treatment groups may be explained, at least in part, because patients were not restratified at the beginning of TP2; however, differences in demographic and disease characteristics at the beginning of TP2 were not clinically relevant. In addition, differences in DAS28-CRP and HAQ-DI at any visit during TP2 were all less than the minimal clinically important difference of 1.0 21 and 0.22, 22 respectively. Overall, the findings from TP2 provide long-term clinical data that complement the existing data demonstrating similarity of PF-SZ-IFX to ref-IFX, including identical amino acid sequences, structural similarity, similar biological function, pharmacokinetic similarity and therapeutic equivalence of PF-SZ-IFX compared with ref-IFX in patients with moderate-to-severe, active RA. This is supported by the fact that PF-SZ-IFX has been approved as a biosimilar of infliximab by regulatory bodies in the European Union, 3 Japan 4 and the USA.
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One of the current concerns with biosimilars is the potential for increased immunogenicity when switching from a reference medicine to a biosimilar of that medicine. 19 Development of ADAs, particularly NAbs, is known to affect the pharmacokinetics of infliximab 1 and other TNFα inhibitors, and could potentially impact efficacy and safety of the medication. 23 Although this study was not powered to assess the impact of switching from ref-IFX to PF-SZ-IFX, the data collected do not provide any indication that switching had any meaningful impact on immunogenicity, pharmacokinetics, efficacy or safety. The percentages of patients who were ADA-positive and NAb-positive at week 30 were similar across all three treatment groups and remained comparable at week 54. Additionally, predose trough serum drug concentrations were generally comparable between the treatment groups throughout TP2. There were no apparent reductions in any of the measures of response between weeks 30 and 54 in any of the treatment groups, including those who switched from ref-IFX to PF-SZ-IFX, and there were no trends suggesting any differences in the safety profile of PF-SZ-IFX after treatment switch from ref-IFX. In clinical practice, it has been observed that switching from a reference medicine to a biosimilar can lead to treatment discontinuation or a switch back to the reference medicine due to reported loss of efficacy. 24 25 It is notable that in this double-blind study, no loss of efficacy was observed and treatment retention rates were similar in TP1 (87.2%; based on safety population) and TP2 (89.4%) and comparable across treatment groups in TP2. This finding suggests that reported loss of efficacy in clinical practice is likely contributable to the 'nocebo effect' phenomenon, 26 27 which could potentially be addressed, at least in part, by providing education for patients before making a shared decision between the treating physician and the patient, to switch to a biosimilar. [28] [29] [30] [31] Multiple biosimilars of infliximab have been approved in the European Union, 3 Contributors ra, BB, tH, HK, Scr, Vt and Sc contributed to the acquisition and interpretation of data. Mr made substantial contributions to study conception and design, study conduct, and analysis and interpretation of data. MZ and cc contributed to the analysis and interpretation of data. gB, SH and Ovr made substantial contributions to interpretation of data. all authors were involved in drafting the manuscript and/or revising it critically for important intellectual content, and read and approved the final manuscript for submission.
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